At Digestive Disease Week 2026 and ISPOR 2026, three studies powered by Celiac Disease Foundation programs and biopharma partnerships demonstrated the growing impact of patient-centered research in celiac disease. Together with Chugai, Teva, Sanofi, and Takeda, the Celiac Disease Foundation helped generate new evidence on the real-world burden of celiac disease, the limits of the gluten-free diet, and adaptable strategies to improve clinical trial recruitment.â
â
These studies reflect the Celiac Disease Foundationâs role as a trusted global patient advocacy organization that connects the lived experience of patients with the scientific, clinical, and operational needs of companies working to develop new treatments.â
â
Link in bio to read more